Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 51 entries
View as:

Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02

Phase: N/A Priority: Normal
NCT ID: NCT00975676 Org: User:
Start: 11/25/08 End: 12/31/16 Due: 12/31/17

Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02308085 Org: User:
Start: 12/04/14 End: 12/31/28 Due: 12/31/29

Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

Phase: N/A Priority: Normal
NCT ID: NCT05718323 Org: User:
Start: 12/20/23 End: 06/30/26 Due: 06/30/27

Afatinib in NSCLC With HER2 Mutation

Phase: N/A Priority: Normal
NCT ID: NCT02369484 Org: User:
Start: 09/16/15 End: 09/15/17 Due: 09/15/18

Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS

Phase: N/A Priority: Normal
NCT ID: NCT00324714 Org: User:
Start: 02/28/03 End: - Due: -

Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy

Phase: N/A Priority: Normal
NCT ID: NCT02129699 Org: User:
Start: 01/06/15 End: 02/29/20 Due: 02/28/21

AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06068153 Org: User:
Start: 03/31/25 End: 12/30/26 Due: 12/30/27

Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05718297 Org: User:
Start: 06/07/24 End: 09/30/24 Due: 09/30/25

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00002784 Org: User:
Start: 06/30/96 End: 12/31/11 Due: 12/31/12

MEtronomic TrEatment Option in Advanced bReast cAncer

Phase: N/A Priority: Normal
NCT ID: NCT02954055 Org: User:
Start: 09/13/17 End: 11/23/22 Due: 11/23/23

Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.

Phase: N/A Priority: Normal
NCT ID: NCT01652469 Org: User:
Start: 08/31/12 End: 12/31/15 Due: 12/31/16

Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT03965468 Org: User:
Start: 11/19/19 End: 12/31/26 Due: 12/31/27

Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03820830 Org: User:
Start: 08/27/19 End: 01/01/29 Due: 01/01/30

Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00553410 Org: User:
Start: 08/31/07 End: 05/15/19 Due: 05/15/20

A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05896566 Org: User:
Start: 01/23/24 End: 06/01/26 Due: 06/01/27

Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I or Stage IIA Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00002528 Org: User:
Start: 05/31/93 End: 08/31/10 Due: 08/31/11

A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT06931717 Org: User:
Start: 09/30/25 End: 03/31/29 Due: 03/31/30

Immunotherapy or Targeted Therapy with or Without Stereotactic Radiosurgery for Patients with Brain Metastases from Melanoma or Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05522660 Org: User:
Start: 11/30/22 End: 12/31/26 Due: 12/31/27

Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98

Phase: N/A Priority: Normal
NCT ID: NCT00369850 Org: User:
Start: 05/31/04 End: 01/31/12 Due: 01/31/13

Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02129556 Org: User:
Start: 12/31/14 End: 08/04/17 Due: 08/04/18

TRial on the Endocrine Activity of Neoadjuvant Degarelix

Phase: N/A Priority: Normal
NCT ID: NCT02005887 Org: User:
Start: 02/28/14 End: 08/25/17 Due: 08/25/18

Cognitive Function in Postmenopausal Women With Breast Cancer Receiving Hormone Therapy on Clinical Trial IBCSG-1-98

Phase: N/A Priority: Normal
NCT ID: NCT00343616 Org: User:
Start: 04/30/05 End: 05/31/09 Due: 05/31/10

Schedules of Nab-Paclitaxel in Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01746225 Org: User:
Start: 04/30/13 End: 03/16/23 Due: 03/16/24

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00066703 Org: User:
Start: 11/03/03 End: 10/23/24 Due: 10/23/25

Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases

Phase: N/A Priority: Normal
NCT ID: NCT00072293 Org: User:
Start: 12/31/01 End: 03/31/17 Due: 03/31/18